Rizzetto F, et al. - In this study, chronic kidney disease (CKD) patients were assessed for the changes in plasma levels of electronegative low-density lipoprotein [LDL(-)] following conservative care using oral sodium bicarbonate (NaHCO₃) supplementation. Findings demonstrated that stabilized renal function and decreased serum levels of LDL(-), a modified proatherogenic lipoprotein, were evident in these patients as a result of receiving conservative care using oral NaHCO₃ supplementation only when mean serum bicarbonate (HCO₃^-) levels approached 22 mM. Overall, this research constitutes evidence that alkali therapy might serve as a preventive strategy to attenuate atherogenesis in CKD patients, in addition to exerting beneficial impact on renal disease progression.